ILC1 as critical gatekeepers in autoimmune kidney damage

Cyril Seillet1,2, Le Xiong1,2

  • 1The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.

PubMed

Insights

Blocking NKp46 signaling reduces organ damage, identifying NKp46+ innate lymphoid cells type 1 (ILC1s) as therapeutic targets in autoimmune diseases like lupus nephritis.

Area of Science:

  • Immunology
  • Autoimmune Diseases
  • Renal Pathology

Background:

  • Natural Killer group 2D (NKG2D) receptor interactions are implicated in autoimmune disease pathogenesis.
  • NKp46 signaling blockade has demonstrated potential in reducing organ injury.

Purpose of the Study:

  • To investigate the role of NKp46+ innate lymphoid cells type 1 (ILC1s) in lupus nephritis pathogenesis.
  • To elucidate the mechanisms by which ILC1s contribute to kidney inflammation and tissue damage.

Main Methods:

  • Analysis of immune cell populations in lupus nephritis models.
  • Assessment of cytokine production by ILC1s.
  • Evaluation of macrophage infiltration and activation.

Main Results:

  • NKp46+ ILC1s were identified as key drivers of kidney inflammation in lupus nephritis.
  • These cells produce CSF2 (colony-stimulating factor 2), promoting pro-inflammatory macrophage expansion.
  • Macrophage infiltration into epithelial niches exacerbates tissue damage.

Conclusions:

  • NKp46+ ILC1s orchestrate kidney inflammation in lupus nephritis via CSF2 production.
  • Targeting NKp46+ ILC1s represents a potential therapeutic strategy for lupus nephritis and related autoimmune conditions.